Axonics (AXNX) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Axonics Revenue Highlights


Latest Revenue (Y)

$366.38M

Latest Revenue (Q)

$114.56M

Main Segment (Y)

Sacral Neuromodulation

Main Geography (Y)

UNITED STATES

Axonics Revenue by Period


Axonics Revenue by Year

DateRevenueChange
2023-12-31$366.38M33.86%
2022-12-31$273.70M51.81%
2021-12-31$180.29M61.64%
2020-12-31$111.53M707.05%
2019-12-31$13.82M1854.74%
2018-12-31$707.00K451.84%
2017-12-31$128.12K100.00%
2016-12-31--

Axonics generated $366.38M in revenue during NA 2023, up 33.86% compared to the previous quarter, and up 51821.64% compared to the same period a year ago.

Axonics Revenue by Quarter

DateRevenueChange
2024-06-30$114.56M25.33%
2024-03-31$91.41M-16.70%
2023-12-31$109.73M17.87%
2023-09-30$93.10M310.06%
2023-06-30$22.70M-67.86%
2023-03-31$70.65M-17.77%
2022-12-31$85.92M22.07%
2022-09-30$70.38M2.04%
2022-06-30$68.98M42.46%
2022-03-31$48.42M-8.87%
2021-12-31$53.13M13.26%
2021-09-30$46.91M2.28%
2021-06-30$45.87M33.44%
2021-03-31$34.37M-1.18%
2020-12-31$34.78M-1.31%
2020-09-30$35.24M131.66%
2020-06-30$15.21M-42.15%
2020-03-31$26.30M164.39%
2019-12-31$9.95M659.82%
2019-09-30$1.31M-12.03%
2019-06-30$1.49M38.16%
2019-03-31$1.08M118.02%
2018-12-31$494.00K145.77%
2018-09-30$201.00K1575.00%
2018-06-30$12.00K100.00%
2018-03-31--100.00%
2017-12-31$118.00-99.91%
2017-09-30$128.00K100.00%
2017-06-30-100.00%
2017-03-31--

Axonics generated $114.56M in revenue during Q2 2024, up 25.33% compared to the previous quarter, and up 162.16% compared to the same period a year ago.

Axonics Revenue Breakdown


Axonics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23
Bulkamid$74.57M
Sacral Neuromodulation$291.81M

Axonics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Sacral Neuromodulation (79.65%), and Bulkamid (20.35%).

Quarterly Revenue by Product

Product/ServiceJun 24Mar 24Dec 23Sep 23Jun 21Mar 21
Sacral Neuromodulation$91.22M$71.68M$217.86M$73.95M$40.19M$32.90M
Bulkamid$23.35M$19.73M$55.42M$19.15M$5.67M$1.47M

Axonics's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Sacral Neuromodulation (79.62%), and Bulkamid (20.38%).

Axonics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
Non-US$15.54M$5.13M$3.75M$3.99M$5.44M
UNITED STATES$284.85M$216.86M$153.84M$107.54M$8.38M

Axonics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (94.83%), and Non-US (5.17%).

Quarterly Revenue by Country

CountryJun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
Non-US$5.04M$4.51M$8.68M$3.57M$1.98M$1.30M$1.24M$1.25M$1.29M$1.35M$722.00K$922.00K$4.25M$2.05M$1.07M$1.10M$565.00K$1.25M
UNITED STATES$89.08M$69.84M$86.58M$72.21M$72.20M$53.85M$69.07M$55.61M$54.47M$37.72M$43.70M$39.15M$41.61M$32.32M$33.71M$34.14M$14.65M$25.05M

Axonics's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (94.64%), and Non-US (5.36%).

Axonics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
MDTMedtronic$32.36B$7.92B
BRKRBruker$2.96B$800.70M
ITGRInteger$1.60B$746.27M
IARTIntegra LifeSciences$1.54B$418.18M
CNMDCONMED$1.24B$316.70M
LIVNLivaNova$1.15B$318.11M
IRTCiRhythm$492.68M$147.54M
AXNXAxonics$366.38M$114.56M
GKOSGlaukos$314.71M$95.69M
KIDSOrthoPediatrics$148.73M$52.80M
SIBNSI-BONE$138.89M$39.97M
LUNGPulmonx$68.67M$20.39M
NPCENeuroPace$65.42M$18.12M
NNOXNano-X Imaging$9.90M$2.55M
MGRMMonogram Orthopaedics$365.00K-
OFIXOrthofix Medical$100.00K$198.62M

AXNX Revenue FAQ


Axonics's yearly revenue for 2023 was $366.38M, representing an increase of 33.86% compared to 2022. The company's yearly revenue for 2022 was $273.7M, representing an increase of 51.81% compared to 2021. AXNX's yearly revenue for 2021 was $180.29M, representing an increase of 61.64% compared to 2020.

Axonics's quarterly revenue for Q2 2024 was $114.56M, a 25.33% increase from the previous quarter (Q1 2024), and a 404.60% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $91.41M, a -16.70% decrease from the previous quarter (Q4 2023), and a 29.38% increase year-over-year (Q1 2023). AXNX's quarterly revenue for Q4 2023 was $109.74M, a 17.87% increase from the previous quarter (Q3 2023), and a 27.72% increase year-over-year (Q4 2022).

Axonics's revenue growth rate for the last 3 years (2021-2023) was 103.22%, and for the last 5 years (2019-2023) was 2551.08%.

Axonics's revenue streams in c 23 are Bulkamid, and Sacral Neuromodulation. Bulkamid generated $74.57M in revenue, accounting 20.35% of the company's total revenue Sacral Neuromodulation generated $291.8M in revenue, accounting 79.65% of the company's total revenue

For the fiscal year ending Dec 23, the largest source of revenue of Axonics was Sacral Neuromodulation. This segment made a revenue of $291.8M, representing 79.65% of the company's total revenue.